Bonus Biogroup’s Post

Great panel at #BiotechShowcase on “Cell & Gene Therapy: New Frontiers, Reaching Patients with Curative Therapies” Moderator: Joel Sandler, Ph.D. Lumanity Panelists: -       Daniel Dornbusch, Excision BioTherapeutics -       Shelley A. Hartman, Aegle Therapeutics -       Daniel Oliver, Rejuvenate Bio -       Lexi Rovner, 64x Bio Some important points were raised: - Investors/partners in the space are the most excited about: Clinical data, One asset farther along >> many earlier stage assets, Clear scalable manufacturing plan.   -  Single administration cure is the holy grail, but: US healthcare system is not set up for single one time treatments that deliver a cure – payers care about what therapy you are replacing for the patients next 2-3 years. Current system does not reward for lifetime curative.  - Indication vs platform focus? This works best when disease experts and technology experts work together, rather than starting at one end of the spectrum. Multi-disciplinary teams will be the most successful. #JPM24 #JPM2024 #CellTherapy #GeneTherapy #AAV

Meet the Sannova team at The American Society of Gene & Cell Therapy (ASGCT) annual meeting, booth # 2048. Conference highlights: ✅Cutting-edge Research ✅Networking Opportunities ✅Professional Development Discover new tools, technologies, and resources essential for advancing your work. Stay up-to-date with industry trends, regulations, and potential future directions in cell and gene therapy. Going to ASGCT2024? Introduce yourself in the comments. #biotech, #immunotherapy, #ASGCT2024 #genetherapy #celltherapy

Think ahead: preparing for challenges to accelerate your #celltherapycommercialization Later this month, Saba Ghassemi (Assistant Professor, Center for Cellular Immunotherapies, University of Pennsylvania), Sabrina Carmichael (Fast Trak Global Technical Leader, Cytiva), Hannah Song (Biologist, Product Development, NIH Center for Cellular Engineering), and Kathryn Henckels (Associate Director, Cell & Gene Therapy API, Johnson & Johnson) will discuss how decisions made during the early stages of process development can have long-lasting effects. Attend this webinar to learn about: • Establishing a cost-effective and reliable manufacturing process • The benefits of implementing the appropriate closed and automated process during early clinical trials • Critical factors necessary for the successful commercialization of an advanced therapy Register for this #webinar below:

Advancement in critical therapeutic niches is one of the factors behind the domination of specialty-based drugs in the pharma industry. CRISPR therapy, RNA-based research, and cell and gene therapy research are some of the technologies being leveraged in the specialty-based arena. What are the implications of the specialty landscape? How are primary care physicians getting familiarized with specialty-based drugs? Christina Fresta, MPH, Strategic Solutions Senior Manager at epocrates, talks about this and more here: https://bit.ly/48P3nk4 #epocrates #healthcareIT #technologyandinnovation #specialtydrugs

🚀 Exciting Updates from ISCT 2024! Last week, our CCRM Nordic team members Fredrik Wessberg, Sarah Callens, Juliana Kovacka, and Stephanie Mattsson had the privilege of attending the ISCT, International Society for Cell & Gene Therapy 2024 conference, and we're thrilled to have witnessed groundbreaking developments and discussions that are shaping the future of cell and gene therapy. Among the notable unveilings was Cytiva's new platform for autologous CAR-Ts, a testament to the industry's growth and continuous innovation in cell processing technologies. Below are some additional highlights: 🔬 CMC - A Persistent Challenge: The conference reaffirmed that CMC remains a hot topic. The field is grappling with a knowledge and resource gap, underscoring the importance of a robust plan from inception to ensure quality and compliance. 💡 Innovative Risk Mitigation: CMC is core to de-risk investments in regenerative medicine. The industry is working on several ways of evolving CMC and risk mitigation, which we think is prudent and paves the way for more confident investments in ATMPs. 🧬 The Promise of iPSCs: The potential of iPSCs continues to excite the scientific community. However, the lack of standardized protocols and benchmarks is a hurdle that needs to be addressed to fully harness their promise. At CCRM Nordic, we're committed to staying at the forefront of these discussions, contributing to the solutions, and driving the industry forward. Reach out if you’re interested in discussing these topics further! Do you have any takeaways worth highlighting? Please share! #ISCT2024 #CellTherapy #GeneTherapy #CMC #iPSC #Innovation #CCRMNordic

Examining recent advances in targeted drug delivery using MSC-derived extracellular vesicles: in this review article, Subhash Chand at University of Nebraska Medical Center and collaborators investigated the characteristics of mesenchymal stem cell-derived EVs, highlighting their potential in therapeutics and drug delivery for various diseases, including the delivery of CRISPR/Cas9 for gene editing https://lnkd.in/exKABYg7 Additionally, they examined the obstacles and challenges associated with the clinical application of MSC-EVs, offering insights into strategies to overcome limitations related to biodistribution and targeted delivery. An article also authored by Anjali Bhat, Anshu Malik, Poonam Yadav, Jessica W. L. Ware and Pratiksha Kakalij #extracellularvesicles #exosomes #stemcells #CRISPR #drugdelivery #Vesiculab

Have you checked out the Azenta Life Sciences #BridgingTheGap webinar series focused on current and future state of the cell and gene therapy space? Featuring prominent guest speakers spanning fields from scientific discovery to clinical introduction of cell and gene therapies, this webinar series roundtable is created by leaders in the field for their peers. Join us and be sure to register for the series! #celltherapy #genetherapy

Discover HER2-postive CTCs predictive value. https://lnkd.in/eeXbdgVk Patients with HER2-negative primary tumours, but HER2-positive CTCs, who received lapatinib in the DETECT III trial, showed improved overall survival compared with those who did not receive the targeted therapy. Harness the potential of ANGLE’s advanced HER2 testing service to enhance longitudinal monitoring, predict therapeutic responses, and optimise subject selection in clinical research. Our innovative approach combines immunofluorescence (IF) staining and fluorescence in situ hybridisation (FISH), to identify and quantify HER2 protein expression and gene amplification in circulating tumour cells (CTCs). For Research Use Only. Not for Use In Diagnostic Procedures. #CancerResearch #HER2 #CirculatingTumourCells

In the high-stakes world of gene editing, securing IP is critical. Our latest blog features insights from Cellistic’s Head of IP, Sergei Kurkin on balancing existing patents with new applications to bring innovative therapies to market. Learn about: → CRISPR and gene-editing innovations → Strategies to maintain exclusivity → Navigating complex IP landscapes Click the link to read more and download the full article on Sergei’s expert opinion on securing a strong IP strategy! 📘🔗 #Cellistic #CellTherapy #GeneEditing #IP #IPStrategy